Quarterly report pursuant to Section 13 or 15(d)

Interim Segment Information (Details)

v2.4.0.6
Interim Segment Information (Details) (USD $)
 3 Months Ended 6 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Segment information        
Revenue $ 9,922,000 $ 20,728,000 $ 20,452,000 $ 43,929,000
Cost of goods sold 6,474,000 14,507,000 13,208,000 29,342,000
Gross profit 3,448,000 6,221,000 7,244,000 14,587,000
Gross margin 34.80% 30.00% 35.40% 33.20%
Operating expenses:        
Sales and marketing 1,824,000 1,695,000 3,708,000 3,694,000
Research and development 1,934,000 1,991,000 3,761,000 4,068,000
General and administrative 2,663,000 1,765,000 5,244,000 3,918,000
Restructuring 57,000 32,000 149,000 277,000
Intangible amortization 211,000 138,000 420,000 277,000
Total operating expenses 6,689,000 5,621,000 13,282,000 12,234,000
Operating income (loss) (3,241,000) 600,000 (6,038,000) 2,353,000
Gain on CNS asset sale   46,000    31,654,000
Other income (expense) 7,000 77,000 91,000 95,000
Interest (expense) 0 (5,000) 0 (5,000)
Income (loss) before income taxes and discontinued operations (3,234,000) 718,000 (5,947,000) 34,097,000
Income tax benefit (expense) 1,059,000 1,852,000 2,032,000 (11,376,000)
Net income (loss) from continuing operations (2,175,000) 2,570,000 (3,915,000) 22,721,000
Westell [Member]
        
Segment information        
Revenue 9,854,000 10,401,000 19,272,000 25,246,000
Cost of goods sold 6,405,000 6,469,000 13,050,000 14,806,000
Gross profit 3,449,000 [1] 3,932,000 6,222,000 10,440,000
Gross margin 35.00% 37.80% 32.30% 41.40%
Operating expenses:        
Sales and marketing 1,831,000 1,446,000 3,706,000 2,928,000
Research and development 1,436,000 1,342,000 2,885,000 2,606,000
General and administrative 1,046,000 604,000 2,294,000 1,422,000
Restructuring 57,000   149,000  
Intangible amortization 210,000 137,000 418,000 275,000
Total operating expenses 4,580,000 3,529,000 9,452,000 7,231,000
Operating income (loss) (1,131,000) 403,000 (3,230,000) 3,209,000
CNS [Member]
        
Segment information        
Revenue 68,000 10,327,000 1,180,000 18,683,000
Cost of goods sold 69,000 8,038,000 158,000 14,536,000
Gross profit (1,000) 2,289,000 1,022,000 4,147,000
Gross margin (1.50%) 22.20% 86.60% 22.20%
Operating expenses:        
Sales and marketing (7,000) 249,000 2,000 766,000
Research and development 498,000 649,000 876,000 1,462,000
General and administrative 540,000 256,000 542,000 551,000
Restructuring 0 32,000    277,000
Intangible amortization 1,000 1,000 2,000 2,000
Total operating expenses 1,032,000 1,187,000 1,422,000 3,058,000
Operating income (loss) (1,033,000) 1,102,000 (400,000) 1,089,000
Unallocated [Member]
        
Segment information        
Revenue            
Cost of goods sold            
Gross profit            
Gross margin            
Operating expenses:        
Sales and marketing            
Research and development            
General and administrative 1,077,000 905,000 2,408,000 1,945,000
Restructuring            
Intangible amortization            
Total operating expenses 1,077,000 905,000 2,408,000 1,945,000
Operating income (loss) (1,077,000) (905,000) (2,408,000) (1,945,000)
Gain on CNS asset sale   46,000   31,654,000
Other income (expense) 7,000 77,000 91,000 95,000
Interest (expense)   (5,000)   (5,000)
Income (loss) before income taxes and discontinued operations (1,070,000) (787,000) (2,317,000) 29,799,000
Income tax benefit (expense) 1,059,000 1,852,000 2,032,000 (11,376,000)
Net income (loss) from continuing operations $ (11,000) $ 1,065,000 $ (285,000) $ 18,423,000
[1] In periods with a net loss, the basic loss per share equals the diluted loss per share as all common stock equivalents are excluded from the per share calculation. The Company had 1.0 million shares represented by options for the three months and 0.5 million shares represented by options for the six months ended September 30, 2011, which were not included in the computation of average diluted shares outstanding because they were anti-dilutive.